Branding/Logomark minus Citation Combined Shape Icon/Bookmark-empty Icon/Copy Icon/Collection Icon/Close Copy 7 no author result Created with Sketch. Icon/Back Created with Sketch. Match!
Blood
IF
16.56
Papers
112780
Papers 112596
1 page of 11.3k pages (113k results)
Newest
Published on Jul 18, 2019in Blood 16.56
Daniel Wolff31
Estimated H-index: 31
(University of Regensburg)
In this issue of Blood , Cuvelier and colleagues from the Applied Biomarkers of Late Effects of Childhood Cancer (ABLE) Consortium evaluate, for the first time, the performance of the National Institutes of Health Consensus Criteria (NIH-CC) for diagnosing chronic graft-versus-host disease (cGVHD) in pediatric patients in a prospective multicenter trial. They demonstrate the utility and limitations of the criteria and provide a benchmark for incidence and severity distribution of late-acute GVHD...
Source Cite
Published on Jul 18, 2019in Blood 16.56
Source Cite
Published on Jul 18, 2019in Blood 16.56
Source Cite
Published on Jul 16, 2019in Blood 16.56
Yoshihiro Gocho2
Estimated H-index: 2
,
Jun Yang42
Estimated H-index: 42
Source Cite
Published on Jul 12, 2019in Blood 16.56
Ciara L. Freeman6
Estimated H-index: 6
,
Robert Kridel18
Estimated H-index: 18
(Princess Margaret Cancer Centre)
+ 11 AuthorsGraham W. Slack18
Estimated H-index: 18
Despite widespread use of bendamustine and rituximab (BR) as frontline therapy for advanced stage follicular lymphoma (FL), little is known about the risk of early progression or incidence of histological transformation. We performed a retrospective analysis of a population-based cohort of 296 patients with advanced stage FL treated with frontline BR and maintenance rituximab. As previously demonstrated, outcomes with this regimen are excellent, with 2-year EFS estimated at 85% [95% CI 80-89%] a...
Source Cite
Published on Jul 12, 2019in Blood 16.56
Source Cite
Published on Jul 12, 2019in Blood 16.56
Source Cite
12345678910